What’s the current market cap for BeOne Medicines AG stock?

BeOne Medicines AG (ONC) has a market cap of $30bn as of June 08, 2026.

What is the P/E ratio for BeOne Medicines AG stock?

The price to earnings (P/E) ratio for BeOne Medicines AG (ONC) stock is 61.33 as of June 08, 2026.

Does BeOne Medicines AG stock pay dividends?

No, BeOne Medicines AG (ONC) stock does not pay dividends to its shareholders as of June 08, 2026.

When is the next BeOne Medicines AG dividend payment date?

BeOne Medicines AG (ONC) stock does not pay dividends to its shareholders.

What is the beta indicator for BeOne Medicines AG?

BeOne Medicines AG (ONC) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy BeOne Medicines AG stock | $ONC Share Price

About BeOne Medicines AG

BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.

Ticker

$ONC

Sector

Health

Primary listing

NASDAQ

Employees

12,000

Headquarters

Basel, Switzerland

Website

beonemedicines.com

ONC Metrics

BasicAdvanced

$30bn

61.33

$4.40

0.49

-

Bulls say / Bears say

Robust Q1 2026 growth: BeOne delivered $1.5 billion in product revenue (up 35% YoY), led by BRUKINSA sales of $1.1 billion, underscoring strong commercial execution in the BTK inhibitor market (Grafa)

Upgraded guidance: Following the Q1 outperformance, management raised full-year 2026 revenue guidance by $100 million to $6.3–$6.5 billion, reflecting confidence in sustained commercial momentum (Investing.com)

Pipeline expansion: On May 13, 2026, the FDA granted accelerated approval to sonrotoclax (Beqalzi) for relapsed/refractory mantle cell lymphoma, adding a second commercial asset to BeOne’s oncology portfolio (Reuters)

BRUKINSA concentration risk: In Q1 2026, BRUKINSA generated $1.1 billion of the $1.5 billion total revenue (≈73%), exposing BeOne to significant single-product risk amid any BTK inhibitor competition or patent expiry (Investing.com) (Grafa)

Regulatory risk: Sonrotoclax’s FDA accelerated approval for relapsed/refractory mantle cell lymphoma is contingent on positive results from the confirmatory CELESTIAL-RRMCL Phase 3 trial (NCT06742996), and failure to verify clinical benefit could lead to withdrawal of the indication (Drugs.com)

Competitive pressure: BeOne’s Beqalzi (sonrotoclax) faces head-to-head competition from AbbVie’s venetoclax and AstraZeneca’s Calquence-venetoclax fixed-duration combo in CLL and MCL, which may constrain pricing and market share (FiercePharma)

Data summarised monthly by Lightyear AI. Last updated on 20 May 2026.

ONC News

AllArticlesVideos

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

MarketBeat·7 days ago

Summit rises after lung cancer drug trial shows 15% higher survival rate than rival's

Reuters·1 week ago

BeOne Medicines Highlights Accelerating Solid Tumor Pipeline with New Data at ASCO 2026

Business Wire·1 week ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.